S-phase fraction combined with other patient and tumor characteristics for the prognosis of node-negative, estrogen-receptor-positive breast cancer

Breast Cancer Research and Treatment

Volumn 51, Issue 3, 1998, Pages 239-253

  Bryant, John ^a,c   Fisher, Bernard ^a,b,c   Gündüz, Nurten ^a,b   Costantino, Joseph P ^a   Emir, Birol ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c NSABP Foundation Inc   (United States)

Author keywords

ER positive breast cancer; Heterogeneity of risk; Prognostic models; S phase fraction; Smoothing splines

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CELL CYCLE S PHASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TUMOR VOLUME;

AGED; BREAST NEOPLASMS; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, ESTROGEN; S PHASE; TUMOR MARKERS, BIOLOGICAL;

EID: 0032442060     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006184428857     Document Type: Article

References (17)

1. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL, Ketner M: A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484, 1989
2. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542, 1996
3. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467, 1988
4. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997
5. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996, by the American Society of Clinical Oncology. J Clin Oncol 14:2843-2877, 1996
6. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 16:793-795, 1998
7. Fisher B, Gunduz N, Costantino J, Fisher ER, Redmond C, Mamounas EP, Siderits R: DNA flow cytometric analysis of primary operable breast cancer: Relation of ploidy and S-phase fraction to outcome of patients in NSABP B-04. Cancer 68:1465-1475, 1991
8. Wilcoxon F: Individual comparisons by ranking methods. Biometrics 1:80-83, 1945
9. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
10. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
11. Gray RJ: Flexible methods for analyzing survival data using splines, with application to breast cancer prognosis. J Am Stat Assoc 87:942-951, 1992
12. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
13. Fisher B, Redmond C, Caplan R: Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project B-06. J Clin Oncol 6:1076-1087, 1988
14. Ewers SB, Attewell R, Baldetorp B, Borg A, Fernö M, Långström E, Killander D: Prognostic significance of flow cytometric DNA analysis and estrogen receptor content in breast carcinomas - A 10 year survival study. Breast Cancer Res Treat 24:115-126, 1992
15. Costantino J, Fisher B, Gunduz N, Fisher E, Mamounas E, Paik S, Dimitrov N, Bowman D, Margolese R, Kavanah M, Shibata H: Tumor size, ploidy, S-phase, and erbB-2 markers in patients with node-negative, ER-positive tumors: Findings from NSABP B-14 [abstract]. Proc Am Soc Clin Oncol 13:64, 1994
16. Stål O, Dufmats M, Hatschek T, Carstensen J, Klintenberg C, Rutqvist L-E, Skoog L, Sullivan S, Wingren S, Nordenskjöld B: S-phase fraction is a prognostic factor in stage I breast carcinoma. J Clin Oncol 11:1717-1722, 1993
17. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Cox C, Duque RE, Hedley DW, Mayall BH, Wheeless L: Guidelines for the implementation of clinical DNA cytometry. Breast Cancer Res Treat 28:61-68, 1993